Circulation杂志是一本国际顶尖期刊,是一本未开放获取期刊。该杂志近三年影响因子分别为:2023年35.5、2022年37.8、2021年39.918。该杂志近三年CiteScore评价分区分别为:2023年45.7区、2022年42.1区、2021年40.5区。该刊专门致力于推进CARDIAC & CARDIOVASCULAR SYSTEMS领域的研究,涵盖了CARDIAC & CARDIOVASCULAR SYSTEMS领域的各个方面,汇集所有专家,促进CARDIAC & CARDIOVASCULAR SYSTEMS领域的更好协作和信息共享。该期刊为CARDIAC & CARDIOVASCULAR SYSTEMS领域的科研人员提供了一个高影响力的论坛,使该领域的科研人员、从业人员和学生能够接触到尖端的经验性调查分析、学术对话以及行业科研成果的最新发展。通过收录高质量的原创论文和评论论文,促进CARDIAC & CARDIOVASCULAR SYSTEMS领域的应用与发展。该期刊还将该领域的创新与应用,以提高研究的质量和实用性。近年来在该刊上发文的国家和地区主要有:Yemen(发文量1)、Wales(发文量22)、Vietnam(发文量5)、Venezuela(发文量5)、Uzbekistan(发文量1)、Uruguay(发文量1)。
Circulation是一本由Lippincott Williams and Wilkins Ltd.出版社发行的知名CARDIAC & CARDIOVASCULAR SYSTEMS期刊。该杂志社联系方式LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621。审稿过程是确保期刊质量的关键环节。Circulation杂志的审稿速度平均需要 约2月 。这一时间周期既体现了编辑部对稿件质量的严格把关,也反映了审稿专家对学术研究的尊重和支持。在这个过程中,作者们可以充分利用这段时间对自己的研究成果进行完善和优化,以提高论文的质量和影响力。如果您对该期刊感兴趣,并希望了解更多关于投稿流程、投稿要求和技巧的信息,您可以咨询本站的客服老师,我们将帮助您了解期刊的投稿要求、审稿流程以及可能遇到的问题,并根据您的具体情况提供相应的建议和解决方案。
CiteScore | SJR | SNIP | CiteScore排名 | |||
---|---|---|---|---|---|---|
45.7 | 8.415 | 6.956 | 学科类别 | 分区 | 排名 | 百分位 |
大类:大类:Medicine
小类:小类:CardiologyandCardiovascularMedicine
|
Q1 | 3/387 | 99% | |||
大类:大类:Medicine
小类:小类:Physiology(medical)
|
Q1 | 2/113 | 98% |
按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
---|---|---|---|---|
学科:CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | 3 / 220 | 98.9% |
学科:PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | 1 / 96 | 99.5% |
按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
---|---|---|---|---|
学科:CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q1 | 1 / 220 | 99.77% |
学科:PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | 1 / 96 | 99.48% |
文章名称
引用次数
Heart Disease and Stroke Statistics-2019 Update A Report From the American Heart Association
1488
Heart Disease and Stroke Statistics-2018 Update A Report From the American Heart Association
1138
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
308
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
286
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
281
Fourth Universal Definition of Myocardial Infarction (2018)
228
Status of Hypertension in China Results From the China Hypertension Survey, 2012-2015
193
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)
138
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
133
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
130
国家/地区
发文量
TUSA
5278
TJapan
879
TCanada
622
TEngland
512
TGERMANY (FED REP GER)
464
TCHINA MAINLAND
382
TNetherlands
335
TItaly
312
TAustralia
293
TFrance
254





